Processa Pharmaceuticals Announces First Patient Dosed in the 300 mg Dose Group with Next Generation Chemotherapy-Capecitabine

March 17, 2023

https://www.globenewswire.com/news-release/2023/03/17/2629471/0/en/Processa-Pharmaceuticals-Announces-First-Patient-Dosed-in-the-300-mg-Dose-Group-with-Next-Generation-Chemotherapy-Capecitabine.html

HANOVER, MD, March 17, 2023 (GLOBE NEWSWIRE) — Processa Pharmaceuticals, Inc. (Nasdaq:PCSA) (“Processa” or the “Company”), a developer of Next Generation Chemotherapies (NGCs), today announced that the Company has dosed the first patient in its NGC-Capecitabine (combination of PCS6422 and capecitabine) 300 mg dose group. The Processa NGCs already have clinical evidence to support their safety and efficacy while they target patients who need better treatment options for their cancer in order to improve survival and/or quality of life.

Read more at globenewswire.com

Related news for (PCSA)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.